Other languages Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.66 ^USD	-6.01%		-6.67%	-2.56%

Apr. 23	Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	MT
Apr. 23	Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 23
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	Apr. 17
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 21
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	Mar. 21
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme	Jan. 17
Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma	Dec. 12
Lisata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents	Nov. 02
Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1	23-10-24
Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma	23-09-06
Lisata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Lisata Therapeutics' LSTA1 Malignant Glioma Treatment Candidate Gets FDA Orphan Drug Label	23-08-08
Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors	23-07-11
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1	23-05-24
Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Lisata Therapeutics Announces Resignation of David Slack as President and Chief Business Officer	23-05-01
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1	23-04-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Other languages

Filters